Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04479280

Enrollment

Registered

2020-07-21

Start date

2020-07-20

Completion date

2020-08-16

Last updated

2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulation Disorder

Brief summary

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Interventions

DEVICESonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA

studying coagulation disorders in COVID19 critically ill patients

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* COVID 19 critically ill patients

Exclusion criteria

* any critical illness not related to COVID 19

Design outcomes

Primary

Measure	Time frame	Description
clot rate formation	30 minutes	measuring how rapid the sample will get clotted

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026